Inclusion Criteria:

- Over 18 years of age

- ER Negative and PR Negative

- Progression of disease in the metastatic setting despite taxane or other
chemotherapeutic therapies including Herceptin (patients on Herceptin may continue
this therapy while on study)

- Maximized chemotherapy in the metastatic setting or patient experienced side effects
contributing to decreased quality of life and elects to defer chemotherapy

- Evaluable disease by either:

- CT Scan with or without contrast (lesions must be greater than 2 mm)

- PET Scan, or Bone Scan, or Plain skeletal films

- Chest wall or skin recurrence (digital photo to capture evaluable disease)

- Evaluable symptoms (pain, shortness of breath, fatigue, anorexia)

- Performance Status of 0, 1, or 2

- Bilateral mammogram performed within one year before registration

Exclusion Criteria:

- Uncontrolled hypercalcemia greater than 11

- Uncontrolled congestive heart failure greater than 2 NYHA class

- Central Nervous System metastasis

- Concomitant steroid use

- Performance Status of greater than 2

- Bilirubin greater than 5.5